查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1951271

胃腸道診斷市場－全球產業規模、佔有率、趨勢、機會及預測（依檢測類型、技術、應用、檢測地點、地區及競爭格局分類，2021-2031年）

Gastrointestinal Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Test Type, By Technology, By Application, By Test Location, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球胃腸道診斷市場預計將從 2025 年的 55.8 億美元成長到 2031 年的 73.3 億美元，複合年成長率為 4.65%。

此細分市場包括用於識別整個消化道（包括腸道、胃和食道）病變的專用檢測試劑盒、影像技術和醫療檢測平台。市場成長的根本促進因素是全球人口老化導致臨床篩檢頻率增加，以及功能性疾病和消化器官系統惡性腫瘤盛行率上升。這些促進因素代表著對疾病監測和早期檢測能力的持續結構性需求成長，使其有別於暫時的產業趨勢。

市場概覽
預測期 2027-2031
市場規模：2025年 55.8億美元
市場規模：2031年 73.3億美元
複合年成長率：2026-2031年 4.65%
成長最快的細分市場 內視鏡檢查
最大的市場 北美洲

根據美國癌症協會預測，2024年美國將新增約152,810例結直腸癌病例，鑑於該疾病負擔沉重，精準診斷工具的緊迫性凸顯。然而，由於分子檢測設備和先進內視鏡系統需要大量資金投入，市場擴張面臨許多障礙。高成本限制了預算緊張的醫療機構使用這些設備，最終阻礙了這些先進診斷技術的廣泛應用。

市場促進因素

慢性胃腸道疾病和胃腸道癌症的日益普遍是全球胃腸道診斷市場的主要驅動力。胃癌、大腸直腸癌和胰臟癌等惡性腫瘤發病率的上升迫使醫療系統優先考慮早期檢測以降低高死亡率，從而持續推動對先進影像技術和成熟內視鏡設備的需求。例如，美國癌症協會發布的《2024年癌症事實與數據》報告顯示，胰臟癌仍是一種高致死率的癌症，預計光是2024年美國就有51,750人死於胰臟癌。為了反映這一需求，Olympus Corporation在2024年5月發布報告稱，其內視鏡解決方案部門在截至2024年3月的會計年度銷售額將達到5,866億日元，證實了該公司對侵入性診斷工具的持續依賴。

同時，受居家和照護現場解決方案需求成長的驅動，市場正經歷重大變革。支付方和患者越來越傾向於選擇非侵入性篩檢方法，例如糞便DNA檢測。與傳統大腸鏡檢查相比，糞便DNA檢測具有更高的依從性和便利性，從而擴大了診斷覆蓋範圍，並惠及服務不足的人。這一轉變對市場領導的財務表現產生了顯著影響。 2024年2月，Exact Sciences公司報告稱，篩檢收入（主要得益於Cologuard檢測）在2023會計年度成長了31%，達到18.7億美元，這充分證明了非侵入性檢測方案的商業性可行性。

市場挑戰

胃腸道診斷市場成長面臨的一大限制因素是先進分子檢測儀器和內視鏡系統所需的高額資本投入。醫療機構，尤其是注重成本控制的農村門診部和社區醫院，往往預算緊張，難以承擔這些平台的高初始購置成本。因此，這些經濟障礙迫使醫療機構長期使用老舊設備，延緩高通量技術的應用，且設備更換週期遠遠超出最佳臨床需求，從根本上阻礙了檢測量的成長。

日益收緊的報銷環境進一步加劇了這種經濟負擔，降低了昂貴診斷設備的投資報酬率。例如，美國胃腸病學會 (ACG) 指出，在最終確定的 2025 年聯邦醫療保險醫師收費標準中，支付轉換係數降低了 2.83%。這些報銷率的降低直接侵蝕了胃腸病診所的營運利潤，並顯著限制了它們投資高成本診斷設備的能力，阻礙了整個市場的成長。

市場趨勢

將人工智慧 (AI) 整合到內視鏡成像系統中，從根本上重新定義了胃腸道病變的檢測標準。深度學習演算法現在可以在電腦輔助檢測系統中即時分析影片串流，識別出人眼可能遺漏的息肉和病變，從而提高腺瘤檢出率這一關鍵指標，並改善患者的治療效果。這些自動化工具強大的臨床療效正在推動市場應用和監管核准。例如，FUJIFILM醫療保健美國公司於 2024 年 3 月宣布，其新核准的CAD EYE AI 系統與標準高清大腸鏡檢查相比，每次大腸鏡檢查的腺瘤檢出率提高了 17%。

同時，市場正轉向一次性內視鏡，以簡化複雜的再處理流程並降低交叉感染的風險。醫院擴大在風險較高的手術中採用這些經過消毒的一次性設備，以確保病患安全並降低與清潔昂貴的可重複使用設備相關的營運成本。這種轉變體現在一次性內視鏡平台的快速商業性擴張上。 2024年11月，Amb A/S公司公佈其內視鏡解決方案部門2023/24會計年度的有機收入成長了19.7%，這反映了一次性內視鏡迅速融入標準臨床實務。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球胃腸道診斷市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依檢測類型（內視鏡檢查、血液檢查、幽門螺旋桿菌檢測、鈣衛蛋白檢測、免疫球蛋白A檢測、其他）
    • 按技術（ELISA、PCR、微生物學、其他）
    • 依應用領域（感染疾病、發炎性腸道疾病、胃食道逆流、癌症等）
    • 按檢測地點（中心檢查室和照護現場）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章 北美胃腸道診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲胃腸道診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區胃腸道診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲胃腸道診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章 南美洲胃腸道診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球胃腸道診斷市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • bioMerieux SA
  • F. Hoffmann-La Roche Ltd.
  • Abbott Laboratories, Inc.
  • Beckman Coulter, Inc.
  • DiaSorin SpA
  • Siemens Healthineers AG
  • QIAGEN NV
  • Meridian Bioscience, Inc.
  • Hologic, Inc.
  • Epitope Diagnostics Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 27336

The Global Gastrointestinal Diagnostics Market is projected to expand from USD 5.58 Billion in 2025 to USD 7.33 Billion by 2031, registering a CAGR of 4.65%. This sector comprises a specialized array of assay kits, imaging technologies, and medical testing platforms engineered to identify pathological conditions across the digestive tract, including the intestines, stomach, and esophagus. The market's growth is fundamentally anchored by an aging global population necessitating frequent clinical screening and the rising prevalence of functional disorders and gastrointestinal malignancies. These drivers represent a durable structural increase in the demand for disease monitoring and early detection capabilities, distinguishing them from temporary industry trends.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 5.58 Billion
Market Size 2031USD 7.33 Billion
CAGR 2026-20314.65%
Fastest Growing SegmentEndoscopy
Largest MarketNorth America

According to the American Cancer Society, approximately 152,810 new cases of colorectal cancer were anticipated to be diagnosed in the United States in 2024, highlighting the urgent need for accurate diagnostic tools given the high disease burden. However, market expansion faces a significant hurdle due to the substantial capital expenditures required for molecular testing equipment and advanced endoscopic systems. This high cost barrier restricts accessibility in budget-constrained healthcare environments, thereby limiting the broader adoption of these advanced diagnostic technologies.

Market Driver

The escalating prevalence of chronic digestive disorders and gastrointestinal cancers acts as the primary catalyst for the Global Gastrointestinal Diagnostics Market. As the incidence of malignancies like gastric, colorectal, and pancreatic cancers rises, healthcare systems are forced to prioritize early detection to lower high mortality rates, creating sustained demand for advanced imaging modalities and established endoscopic hardware. For example, the American Cancer Society's 'Cancer Facts & Figures 2024' noted that pancreatic cancer remains highly lethal, with an estimated 51,750 deaths expected in the U.S. alone that year. Reflecting this demand, Olympus Corporation reported in May 2024 that its Endoscopic Solutions Division achieved revenue of 586.6 billion JPY for the fiscal year ended March 31, 2024, confirming the continued reliance on invasive diagnostic tools.

Concurrently, the market is undergoing a significant transformation driven by the growing preference for at-home and point-of-care diagnostic solutions. Payers and patients are increasingly favoring non-invasive screening methods, such as stool-based DNA tests, which improve compliance and convenience compared to traditional colonoscopies, thus extending diagnostic reach to under-screened populations. This shift has notably impacted the financial performance of market leaders; Exact Sciences Corp. reported in February 2024 that its screening revenue, largely driven by Cologuard tests, grew by 31 percent to 1.87 billion USD for the full year 2023, demonstrating the commercial viability of non-invasive options.

Market Challenge

A major restraint on the growth of the gastrointestinal diagnostics market is the significant capital expense required for advanced molecular testing equipment and endoscopic systems. Healthcare facilities, particularly outpatient clinics and community hospitals in cost-sensitive areas, often operate with limited budgets that cannot support the high upfront procurement costs of these platforms. Consequently, these financial barriers force the prolonged use of legacy instrumentation and delay the adoption of higher-throughput technologies, leading to a structural deceleration in volume growth as equipment replacement cycles extend well beyond optimal clinical timelines.

This economic strain is further intensified by a contracting reimbursement landscape that reduces the return on investment for expensive diagnostic assets. For instance, the American College of Gastroenterology noted that the finalized 2025 Medicare Physician Fee Schedule included a 2.83 percent reduction in the payment conversion factor. Such cuts in reimbursement rates directly erode the operating margins of gastroenterology practices, severely limiting their financial capacity to invest in high-cost diagnostic capital equipment and thereby hindering the market's overall growth trajectory.

Market Trends

The integration of artificial intelligence into endoscopic imaging systems is fundamentally redefining detection standards for gastrointestinal pathologies. Deep learning algorithms are now utilized in computer-aided detection systems to analyze video feeds in real-time, identifying polyps and lesions that might otherwise be missed by human observation, thereby addressing the critical variable of adenoma detection rates and improving patient outcomes. The superior clinical efficacy of these automated tools is driving market adoption and regulatory clearances; for example, Fujifilm Healthcare Americas Corporation announced in March 2024 that its newly cleared CAD EYE AI system demonstrated a 17 percent higher adenoma per colonoscopy rate compared to standard high-definition colonoscopy.

Simultaneously, the market is shifting toward single-use disposable endoscopes to eliminate complex reprocessing workflows and mitigate cross-contamination risks. Hospitals are increasingly adopting these sterile, one-time-use devices for high-risk procedures to ensure patient safety and reduce the operational overhead associated with cleaning capital-intensive reusable equipment. This transition is evident in the rapid commercial expansion of disposable platforms; Ambu A/S reported in November 2024 that organic revenue for its Endoscopy Solutions division increased by 19.7 percent for the 2023/24 financial year, reflecting the accelerating integration of disposable scopes into standard clinical practice.

Key Market Players

  • bioMerieux S.A.
  • F. Hoffmann-La Roche Ltd.
  • Abbott Laboratories, Inc.
  • Beckman Coulter, Inc.
  • DiaSorin S.p.A
  • Siemens Healthineers AG
  • QIAGEN N.V.
  • Meridian Bioscience, Inc.
  • Hologic, Inc.
  • Epitope Diagnostics Inc.

Report Scope

In this report, the Global Gastrointestinal Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Gastrointestinal Diagnostics Market, By Test Type

  • Endoscopy
  • Blood Test
  • H. pylori Test
  • Calprotectin Test
  • Immunoglobulin A Test
  • and Others

Gastrointestinal Diagnostics Market, By Technology

  • ELISA
  • PCR
  • Microbiology
  • and Others

Gastrointestinal Diagnostics Market, By Application

  • Infection
  • Inflammatory Bowel Disease
  • Gastroesophageal Reflux Disease
  • Cancer
  • and Others

Gastrointestinal Diagnostics Market, By Test Location

  • Central laboratories and Point-of-Care

Gastrointestinal Diagnostics Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Gastrointestinal Diagnostics Market.

Available Customizations:

Global Gastrointestinal Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Gastrointestinal Diagnostics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Test Type (Endoscopy, Blood Test, H. pylori Test, Calprotectin Test, Immunoglobulin A Test, and Others)
    • 5.2.2. By Technology (ELISA, PCR, Microbiology, and Others)
    • 5.2.3. By Application (Infection, Inflammatory Bowel Disease, Gastroesophageal Reflux Disease, Cancer, and Others)
    • 5.2.4. By Test Location (Central laboratories and Point-of-Care)
    • 5.2.5. By Region
    • 5.2.6. By Company (2025)
  • 5.3. Market Map

6. North America Gastrointestinal Diagnostics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Test Type
    • 6.2.2. By Technology
    • 6.2.3. By Application
    • 6.2.4. By Test Location
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Gastrointestinal Diagnostics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Test Type
        • 6.3.1.2.2. By Technology
        • 6.3.1.2.3. By Application
        • 6.3.1.2.4. By Test Location
    • 6.3.2. Canada Gastrointestinal Diagnostics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Test Type
        • 6.3.2.2.2. By Technology
        • 6.3.2.2.3. By Application
        • 6.3.2.2.4. By Test Location
    • 6.3.3. Mexico Gastrointestinal Diagnostics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Test Type
        • 6.3.3.2.2. By Technology
        • 6.3.3.2.3. By Application
        • 6.3.3.2.4. By Test Location

7. Europe Gastrointestinal Diagnostics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Test Type
    • 7.2.2. By Technology
    • 7.2.3. By Application
    • 7.2.4. By Test Location
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Gastrointestinal Diagnostics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Test Type
        • 7.3.1.2.2. By Technology
        • 7.3.1.2.3. By Application
        • 7.3.1.2.4. By Test Location
    • 7.3.2. France Gastrointestinal Diagnostics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Test Type
        • 7.3.2.2.2. By Technology
        • 7.3.2.2.3. By Application
        • 7.3.2.2.4. By Test Location
    • 7.3.3. United Kingdom Gastrointestinal Diagnostics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Test Type
        • 7.3.3.2.2. By Technology
        • 7.3.3.2.3. By Application
        • 7.3.3.2.4. By Test Location
    • 7.3.4. Italy Gastrointestinal Diagnostics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Test Type
        • 7.3.4.2.2. By Technology
        • 7.3.4.2.3. By Application
        • 7.3.4.2.4. By Test Location
    • 7.3.5. Spain Gastrointestinal Diagnostics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Test Type
        • 7.3.5.2.2. By Technology
        • 7.3.5.2.3. By Application
        • 7.3.5.2.4. By Test Location

8. Asia Pacific Gastrointestinal Diagnostics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Test Type
    • 8.2.2. By Technology
    • 8.2.3. By Application
    • 8.2.4. By Test Location
    • 8.2.5. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Gastrointestinal Diagnostics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Test Type
        • 8.3.1.2.2. By Technology
        • 8.3.1.2.3. By Application
        • 8.3.1.2.4. By Test Location
    • 8.3.2. India Gastrointestinal Diagnostics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Test Type
        • 8.3.2.2.2. By Technology
        • 8.3.2.2.3. By Application
        • 8.3.2.2.4. By Test Location
    • 8.3.3. Japan Gastrointestinal Diagnostics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Test Type
        • 8.3.3.2.2. By Technology
        • 8.3.3.2.3. By Application
        • 8.3.3.2.4. By Test Location
    • 8.3.4. South Korea Gastrointestinal Diagnostics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Test Type
        • 8.3.4.2.2. By Technology
        • 8.3.4.2.3. By Application
        • 8.3.4.2.4. By Test Location
    • 8.3.5. Australia Gastrointestinal Diagnostics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Test Type
        • 8.3.5.2.2. By Technology
        • 8.3.5.2.3. By Application
        • 8.3.5.2.4. By Test Location

9. Middle East & Africa Gastrointestinal Diagnostics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Test Type
    • 9.2.2. By Technology
    • 9.2.3. By Application
    • 9.2.4. By Test Location
    • 9.2.5. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Gastrointestinal Diagnostics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Test Type
        • 9.3.1.2.2. By Technology
        • 9.3.1.2.3. By Application
        • 9.3.1.2.4. By Test Location
    • 9.3.2. UAE Gastrointestinal Diagnostics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Test Type
        • 9.3.2.2.2. By Technology
        • 9.3.2.2.3. By Application
        • 9.3.2.2.4. By Test Location
    • 9.3.3. South Africa Gastrointestinal Diagnostics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Test Type
        • 9.3.3.2.2. By Technology
        • 9.3.3.2.3. By Application
        • 9.3.3.2.4. By Test Location

10. South America Gastrointestinal Diagnostics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Test Type
    • 10.2.2. By Technology
    • 10.2.3. By Application
    • 10.2.4. By Test Location
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Gastrointestinal Diagnostics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Test Type
        • 10.3.1.2.2. By Technology
        • 10.3.1.2.3. By Application
        • 10.3.1.2.4. By Test Location
    • 10.3.2. Colombia Gastrointestinal Diagnostics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Test Type
        • 10.3.2.2.2. By Technology
        • 10.3.2.2.3. By Application
        • 10.3.2.2.4. By Test Location
    • 10.3.3. Argentina Gastrointestinal Diagnostics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Test Type
        • 10.3.3.2.2. By Technology
        • 10.3.3.2.3. By Application
        • 10.3.3.2.4. By Test Location

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Gastrointestinal Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. bioMerieux S.A.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. F. Hoffmann-La Roche Ltd.
  • 15.3. Abbott Laboratories, Inc.
  • 15.4. Beckman Coulter, Inc.
  • 15.5. DiaSorin S.p.A
  • 15.6. Siemens Healthineers AG
  • 15.7. QIAGEN N.V.
  • 15.8. Meridian Bioscience, Inc.
  • 15.9. Hologic, Inc.
  • 15.10. Epitope Diagnostics Inc.

16. Strategic Recommendations

17. About Us & Disclaimer